E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 37.7 HKD -2.71% Market Closed
Market Cap: 12.3B HKD
Have any thoughts about
Everest Medicines Ltd?
Write Note

Income Statement

Earnings Waterfall
Everest Medicines Ltd

Revenue
418.6m CNY
Cost of Revenue
-101.5m CNY
Gross Profit
317m CNY
Operating Expenses
-1.1B CNY
Operating Income
-750.8m CNY
Other Expenses
-302.5m CNY
Net Income
-1.1B CNY

Income Statement
Everest Medicines Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024
Revenue
Revenue
0
N/A
0
N/A
0
N/A
0
N/A
1
+1 933%
13
+1 065%
21
+61%
126
+510%
419
+232%
Gross Profit
Cost of Revenue
0
0
0
(0)
(0)
(5)
(8)
(34)
(102)
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
1
+2 194%
8
+1 046%
13
+60%
92
+602%
317
+246%
Operating Income
Operating Expenses
(446)
(688)
(1 086)
(1 049)
(1 263)
(1 413)
(1 238)
(943)
(1 068)
Selling, General & Administrative
(156)
(303)
(448)
(424)
(537)
(583)
(467)
(379)
(521)
Research & Development
(305)
(365)
(608)
(599)
(693)
(790)
(719)
(490)
(453)
Depreciation & Amortization
(14)
(20)
(33)
(31)
(36)
(40)
(50)
(68)
(67)
Other Operating Expenses
30
1
3
5
4
0
(2)
(6)
(26)
Operating Income
(446)
N/A
(688)
-54%
(1 086)
-58%
(1 049)
+3%
(1 262)
-20%
(1 405)
-11%
(1 225)
+13%
(851)
+31%
(751)
+12%
Pre-Tax Income
Interest Income Expense
(382)
(23)
(4 945)
47
(27)
(144)
(29)
57
47
Non-Reccuring Items
0
0
0
0
0
1 303
1 250
(53)
(357)
Total Other Income
(10)
(4 948)
(10)
(6)
(5)
(2)
1
3
7
Pre-Tax Income
(838)
N/A
(5 658)
-575%
(6 041)
-7%
(1 009)
+83%
(1 294)
-28%
(247)
+81%
(3)
+99%
(844)
-29 582%
(1 053)
-25%
Net Income
Tax Provision
0
0
0
0
0
(0)
(0)
0
0
Income from Continuing Operations
(838)
(5 658)
(6 041)
(1 009)
(1 294)
(247)
(3)
(844)
(1 053)
Net Income (Common)
(838)
N/A
(5 658)
-575%
(6 041)
-7%
(1 009)
+83%
(1 294)
-28%
(247)
+81%
(3)
+99%
(844)
-29 499%
(1 053)
-25%
EPS (Diluted)
-3.81
N/A
-66.29
-1 640%
-20.58
+69%
-3.44
+83%
-4.39
-28%
-0.83
+81%
0
N/A
-2.7
N/A
-3.27
-21%

See Also

Discover More